GNBT ALERT – PPS Could Break 52 Week $25 High As Apex Clearing Firm Buys Back Phantom GNBT Stock Mistakenly Issued In Tech Glitch

New York, NY – November 23, 2018 – Generex Biotechnology Corp (OTCQB: GNBT) issued an announcement on Wednesday this week to warn shareholders that Apex Clearing Firm had mistakenly issued phantom GNBT stock.  Sales of the phantom stock were the likely cause of a GNBT PPS decline on Wednesday.  Any sale of the phantom stock is effectively a short sale and Apex will be required to purchase shares to cover such short sales.  All short sales will have to be covered with the purchase of stock within three trading days.  The APEX buy back could trigger a GNBT run back to the recent 52 week high of $25.  GNBT has been very active of late with major acquisitions and the initiation of clinical trials.  The combination of positive GNBT news and the APEX buy back could give investors a substantial ROI.

Generex is currently a quiet giant of a pharmaceutical company that most people probably are not yet aware even exists.  Do a little research and you will find Generex is loaded with proprietary, intellectual property protected pharmaceutical technology. 

Learn more about Generex at

DISCLAIMER: (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.